Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.81M
Enterprise Value-$22.53M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-12.46
Enterprise Value/Revenue-1.26
Enterprise Value/Gross Profit-3.58
Enterprise Value/Ebitda7.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetModest debt and low debt/equity (~0.16) provide the company with financial flexibility and lower near-term refinancing risk. This conservatively financed balance sheet supports operational continuity and selective investment while management executes a multi-quarter turnaround, reducing solvency pressure.
Margin Recovery In 2025Rebounding gross margin and a materially improved net margin in 2025 indicate improving product mix or cost control. Sustained margin recovery can meaningfully lower cash burn, improve unit economics and increase the odds that revenue stabilization will translate into progressively smaller losses over the medium term.
2026 Equity Incentive PlanImplementing an equity incentive plan aligns management and employee pay with shareholder outcomes and supports talent retention. Structurally this improves the company's ability to attract/retain skill sets needed for R&D, commercialization and execution—key to a sustained operational turnaround.
Bears Say
Multi-year Revenue DeclineA steep, multi-year top-line contraction erodes scale and market presence. Shrinking revenue hinders fixed-cost absorption, reduces pricing and distribution leverage, and increases the structural difficulty of returning to sustainable profitability absent a durable demand or product revival.
Persistent Negative Cash FlowConsistent negative operating and free cash flow signals ongoing cash burn, forcing reliance on external financing or equity dilution to fund operations. Over months this constrains R&D, commercial investment and strategic flexibility, and elevates liquidity and dilution risk if losses persist.
Dual-class Governance ConcentrationThe new dual-class share structure concentrates voting power and can entrench incumbent control. Over the medium term this raises governance risk, may reduce minority shareholder influence and could deter governance-focused investors, limiting external oversight of strategic choices.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.81M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 563,338 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―